LucentisㆍVenclexta benefits cut by 30% and 12.2%, Vfend increases by 19.5%
Revision in the pharmaceutical benefit list and the table of the upper limit of benefits RinvoqㆍNuvorozet newly added
[Newsmp] The upper limit of health insurance benefits for Novartis’ Lucentis and AbbVie’s Venclexta will be drastically reduced from the 1st of next month.
For Pfizer’s Vfend Tab. and Young Poong Pharmaceutical’s Clomiphen Citrate Tab. Youngpoong, the upper limits are expected to be increased, while company names will be changed for Alvesco Inhaler, Bonviva Inj., Valcyte Tab., and Duoray Inj..
On the 26th, the Ministry of Health and Welfare revised and issued a revision of the ‘Pharmaceutical benefit list and the table of the upper limit of benefits.’
According to the notice, AbbVie’s Rinvoq ER Tab. 30mg and Chong Kun Dang Pharmaceutical’s Nuvorozet Tab. 40/2.5/10/10mg will be newly listed. The maximum amount of benefits was set at KRW 31,628 and KRW 1,810.
Four items of Fexuprazan, Fexuclue Tab. 10mg (Daewoong Pharmaceutical), Wecab Tab. 10mg (Daewoong Bio), Velox Cab Tab. 10mg (iN Therapeutics), and Abcito Tab. 10mg (HanAll Biopharma) will also be listed with 10mg. The upper limit is KRW 376 per tablet.
Chonnam National University Hwasun Hospital’s self-developed radiopharmaceuticals Fludeoxyglucose 18F Injection was newly added to the list at KRW 28,000 per mCI.
In the meantime, the supplier for Alvesco Inhaler altered and listed from AstraZeneca to SK Chemicals, Bonviva Inj. from Handok to Jeil Pharmaceutical, Valcyte Tab. 450mg from Roche to Chong Kun Dang Pharmaceutical, and two items of Duoray Inj. 270mg from DongKook Pharmaceutical to Dongkook Life Science.
Among the existing listed items, the upper limit for Lucentis Inj. 10mg/ml(3mg/0.3mL), Lucentis Inj. 10mg/ml(2.3mg/0.23mL), and Lucentis Prefilled Syringe (0.5mg/0.05mL) (1.65mg/0.165mL) will be cut by 30%, and Venclexta Tab. 10mg, 50mg and 100mg by 12.2%.
Kwang Dong Pharmaceutical’ Hyalsix Inj. (2.04g/2mL), Jeil Pharmaceutical’s Hyaltanwon Inj. (2.04g/2mL), Kyung Dong Pharmaceutical’s Hyalbonpluswons Inj., Yooyoung Pharmaceutical’s Resyno-ONE Inj., and Daewon Pharmaceutical’s Bonissen Once Inj. will all be reduced by 2.9%.
On the other hand, the upper limit of benefits for Clomiphen Citrate Tab. Youngpoong 50mg looks forward to being raised by 157.3% and Vfend Tab. 200mg by 19.5%
Dong-A ST’s Teribone S.C. Inj. 56.5μg, which was scheduled to lower the maximum amount on the 1st of the next month, will maintain the existing upper limit and will be reduced by 23.5% on Feb. 1 of next year.